154 related articles for article (PubMed ID: 21175789)
1. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.
Tsang DP; Cheng AS
J Gastroenterol Hepatol; 2011 Jan; 26(1):19-27. PubMed ID: 21175789
[TBL] [Abstract][Full Text] [Related]
2. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
[TBL] [Abstract][Full Text] [Related]
3. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.
Liu L; Xiao B; Hirukawa A; Smith HW; Zuo D; Sanguin-Gendreau V; McCaffrey L; Nam AJ; Muller WJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303010120. PubMed ID: 37549258
[TBL] [Abstract][Full Text] [Related]
4. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Zhang T; Gong Y; Meng H; Li C; Xue L
Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J; Wang W; Zhang Y; Cieślik M; Guo J; Tan M; Green MD; Wang W; Lin H; Li W; Wei S; Zhou J; Li G; Jing X; Vatan L; Zhao L; Bitler B; Zhang R; Cho KR; Dou Y; Kryczek I; Chan TA; Huntsman D; Chinnaiyan AM; Zou W
J Clin Invest; 2020 May; 130(5):2712-2726. PubMed ID: 32027624
[TBL] [Abstract][Full Text] [Related]
6. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
7. Transcription Factors and Cancer: Approaches to Targeting.
Shiah JV; Johnson DE; Grandis JR
Cancer J; 2023 Jan-Feb 01; 29(1):38-46. PubMed ID: 36693157
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.
Talukdar PD; Chatterji U
Signal Transduct Target Ther; 2023 Nov; 8(1):427. PubMed ID: 37953273
[TBL] [Abstract][Full Text] [Related]
9. Signaling epigenetics: novel insights on cell signaling and epigenetic regulation.
Arzate-Mejía RG; Valle-García D; Recillas-Targa F
IUBMB Life; 2011 Oct; 63(10):881-95. PubMed ID: 21901818
[TBL] [Abstract][Full Text] [Related]
10. Surgery in the era of the 'omics revolution.
Beggs AD; Dilworth MP
Br J Surg; 2015 Jan; 102(2):e29-40. PubMed ID: 25627134
[TBL] [Abstract][Full Text] [Related]
11. The 'omics' revolution: redefining the understanding and treatment of allergic skin diseases.
Oliva M; Renert-Yuval Y; Guttman-Yassky E
Curr Opin Allergy Clin Immunol; 2016 Oct; 16(5):469-76. PubMed ID: 27490125
[TBL] [Abstract][Full Text] [Related]
12. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract][Full Text] [Related]
13. Cancer and the omics revolution.
Epstein RJ; Lin FP
Aust Fam Physician; 2017; 46(4):189-193. PubMed ID: 28376570
[TBL] [Abstract][Full Text] [Related]
14. Beyond receptors and signaling: epigenetic factors in the regulation of innate immunity.
Mehta S; Jeffrey KL
Immunol Cell Biol; 2015 Mar; 93(3):233-44. PubMed ID: 25559622
[TBL] [Abstract][Full Text] [Related]
15. How Do Genomes Create Novel Phenotypes? Insights from the Loss of the Worker Caste in Ant Social Parasites.
Smith CR; Helms Cahan S; Kemena C; Brady SG; Yang W; Bornberg-Bauer E; Eriksson T; Gadau J; Helmkampf M; Gotzek D; Okamoto Miyakawa M; Suarez AV; Mikheyev A
Mol Biol Evol; 2015 Nov; 32(11):2919-31. PubMed ID: 26226984
[TBL] [Abstract][Full Text] [Related]
16. Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease.
Zaneveld J; Wang F; Wang X; Chen R
Sci China Life Sci; 2013 Feb; 56(2):125-33. PubMed ID: 23393028
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
18. lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma.
Wozniak M; Czyz M
Front Mol Biosci; 2023; 10():1170026. PubMed ID: 37325482
[TBL] [Abstract][Full Text] [Related]
19. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
